MX372934B - Compuestos de imidazopiridina y sus usos. - Google Patents
Compuestos de imidazopiridina y sus usos.Info
- Publication number
- MX372934B MX372934B MX2015009950A MX2015009950A MX372934B MX 372934 B MX372934 B MX 372934B MX 2015009950 A MX2015009950 A MX 2015009950A MX 2015009950 A MX2015009950 A MX 2015009950A MX 372934 B MX372934 B MX 372934B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- imidazopyridine compounds
- processes
- compounds
- substituted
- Prior art date
Links
- 150000005232 imidazopyridines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- NWGCVECXOLSHAD-UHFFFAOYSA-N 4-imidazo[1,2-a]pyridin-2-ylbenzamide Chemical class C1=CC(C(=O)N)=CC=C1C1=CN(C=CC=C2)C2=N1 NWGCVECXOLSHAD-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 for example Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759123P | 2013-01-31 | 2013-01-31 | |
| PCT/CA2014/050062 WO2014117274A1 (en) | 2013-01-31 | 2014-01-31 | Imidazopyridine compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015009950A MX2015009950A (es) | 2016-02-05 |
| MX372934B true MX372934B (es) | 2020-04-08 |
Family
ID=51261357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015009950A MX372934B (es) | 2013-01-31 | 2014-01-31 | Compuestos de imidazopiridina y sus usos. |
Country Status (17)
| Country | Link |
|---|---|
| US (9) | US9598409B2 (OSRAM) |
| EP (3) | EP3998267A1 (OSRAM) |
| JP (1) | JP6373280B2 (OSRAM) |
| KR (1) | KR102120513B1 (OSRAM) |
| CN (2) | CN107485612B (OSRAM) |
| AU (1) | AU2014211962B2 (OSRAM) |
| BR (1) | BR112015018317B1 (OSRAM) |
| CA (1) | CA2898665C (OSRAM) |
| DK (2) | DK3381917T3 (OSRAM) |
| ES (2) | ES2674087T3 (OSRAM) |
| MX (1) | MX372934B (OSRAM) |
| NO (1) | NO2910833T3 (OSRAM) |
| PL (2) | PL3381917T3 (OSRAM) |
| PT (2) | PT2951177T (OSRAM) |
| RU (1) | RU2656593C2 (OSRAM) |
| TR (1) | TR201807602T4 (OSRAM) |
| WO (1) | WO2014117274A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117274A1 (en) * | 2013-01-31 | 2014-08-07 | Neomed Institute | Imidazopyridine compounds and uses thereof |
| CA2969952A1 (en) | 2014-12-09 | 2016-06-16 | Adam James Davenport | 1,3-thiazol-2-yl substituted benzamides |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| CN116854693A (zh) * | 2016-09-30 | 2023-10-10 | 阿沙纳生物科学公司 | P2x3和/或p2x2/3化合物及方法 |
| EP3339307A1 (en) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| EP3862000B1 (en) | 2018-10-05 | 2023-10-18 | Shionogi & Co., Ltd | Medicine for treating chronic cough |
| AU2019358327B2 (en) * | 2018-10-10 | 2025-04-24 | Glaxosmithkline Intellectual Property (No. 3) Limited | Treatment of pruritus with P2X3 antagonists |
| ES3033466T3 (en) | 2018-11-13 | 2025-08-04 | Glaxosmithkline Intellectual Property No 3 Ltd | Crystalline forms of p2x3 modulator methyl (s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate |
| SG11202106706TA (en) * | 2018-12-29 | 2021-07-29 | Wuhan Ll Science And Technology Development Co Ltd | Heterocyclic compound intermediate, preparation method therefor and application thereof |
| CN113727716A (zh) * | 2019-02-25 | 2021-11-30 | 贝卢斯医疗咳嗽病公司 | 采用p2x3调节剂的治疗 |
| CN112409331B (zh) * | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CA3184277A1 (en) * | 2020-02-14 | 2021-08-19 | Bellus Health Cough Inc. | Preparation of a p2x3 antagonist |
| WO2021161105A1 (en) * | 2020-02-14 | 2021-08-19 | Bellus Health Cough Inc. | P2x3 modulators |
| CN113549068B (zh) * | 2020-04-24 | 2022-12-02 | 上海拓界生物医药科技有限公司 | 一类新型咪唑并吡啶化合物、其制备方法及其在医药上的应用 |
| CN113754654A (zh) * | 2020-06-05 | 2021-12-07 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物及其用途 |
| CN114085220B (zh) * | 2020-06-22 | 2023-06-16 | 上海海雁医药科技有限公司 | 取代的吗啉-4-羧酸酯衍生物、其组合物及医药上的用途 |
| US20230406850A1 (en) * | 2020-06-29 | 2023-12-21 | Wuhan Ll Science And Technology Development Co., Ltd. | Crystalline form of heterocyclic compound, preparation method therefor and application thereof |
| CN113912601B (zh) * | 2020-07-10 | 2023-06-06 | 上海拓界生物医药科技有限公司 | 一类新的咪唑并[1,2-a]吡啶类衍生物、其制备方法及医药用途 |
| WO2022033567A1 (zh) * | 2020-08-13 | 2022-02-17 | 上海拓界生物医药科技有限公司 | 苯并咪唑类衍生物、其制备方法及医药用途 |
| CN112485351A (zh) * | 2020-11-18 | 2021-03-12 | 天津华津制药有限公司 | 一种右佐匹克隆光学异构体的检测方法 |
| WO2022117062A1 (zh) * | 2020-12-04 | 2022-06-09 | 上海拓界生物医药科技有限公司 | 含有稠合三环的化合物及其医药用途 |
| CN114805237A (zh) * | 2021-01-22 | 2022-07-29 | 武汉人福创新药物研发中心有限公司 | 杂环类化合物的制备方法及其中间体 |
| CN114805340A (zh) * | 2021-01-22 | 2022-07-29 | 武汉人福创新药物研发中心有限公司 | 咪唑并吡啶类化合物的制备方法及其中间体 |
| WO2022258059A1 (zh) * | 2021-06-10 | 2022-12-15 | 武汉朗来科技发展有限公司 | 一种药物组合物、制剂及其制备方法和应用 |
| WO2022268218A1 (zh) * | 2021-06-24 | 2022-12-29 | 武汉朗来科技发展有限公司 | 一种杂环烷基类化合物的制备方法、其中间体及其应用 |
| WO2023021328A1 (en) * | 2021-08-17 | 2023-02-23 | Bellus Health Cough Inc. | Preparation of a p2x3 antagonist |
| WO2023020156A1 (zh) * | 2021-08-20 | 2023-02-23 | 苏州璞正医药有限公司 | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 |
| WO2024194352A1 (en) | 2023-03-23 | 2024-09-26 | Glaxosmithkline Intellectual Property (No.3) Limited | Deuterated p2x3 modulators |
| WO2025125445A1 (en) | 2023-12-12 | 2025-06-19 | Glaxosmithkline Intellectual Property (No.3) Limited | Process of manufacture of p2x3 antagonists including camlipixant |
| WO2025191081A1 (en) | 2024-03-15 | 2025-09-18 | Glaxosmithkline Intellectual Property (No.3) Limited | Crystalline form of camlipixant |
| WO2025210540A1 (en) | 2024-04-02 | 2025-10-09 | Assia Chemical Industries Ltd. | Solid state forms of camlipixant and process for preparation thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9119920D0 (en) | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| SE0102808D0 (sv) * | 2001-08-22 | 2001-08-22 | Astrazeneca Ab | New compounds |
| BRPI0515897A (pt) | 2004-09-24 | 2008-08-12 | Astrazeneca Ab | composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto |
| DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
| BRPI0714315B8 (pt) * | 2006-06-29 | 2021-05-25 | Hoffmann La Roche | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende |
| US20090099195A1 (en) | 2007-05-08 | 2009-04-16 | Astrazeneca Ab | Therapeutic Compounds 570 |
| US9238647B2 (en) * | 2009-03-23 | 2016-01-19 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| BR112012011518B8 (pt) * | 2009-11-18 | 2023-01-10 | Astrazeneca Ab | Compostos, composição farmacêutica, kit e usos de um composto |
| WO2014117274A1 (en) | 2013-01-31 | 2014-08-07 | Neomed Institute | Imidazopyridine compounds and uses thereof |
-
2014
- 2014-01-31 WO PCT/CA2014/050062 patent/WO2014117274A1/en not_active Ceased
- 2014-01-31 KR KR1020157023171A patent/KR102120513B1/ko active Active
- 2014-01-31 EP EP21195015.9A patent/EP3998267A1/en active Pending
- 2014-01-31 DK DK18158586.0T patent/DK3381917T3/da active
- 2014-01-31 BR BR112015018317-4A patent/BR112015018317B1/pt active IP Right Grant
- 2014-01-31 EP EP14745722.0A patent/EP2951177B1/en active Active
- 2014-01-31 AU AU2014211962A patent/AU2014211962B2/en active Active
- 2014-01-31 ES ES14745722.0T patent/ES2674087T3/es active Active
- 2014-01-31 PT PT147457220T patent/PT2951177T/pt unknown
- 2014-01-31 US US14/764,404 patent/US9598409B2/en active Active
- 2014-01-31 ES ES18158586T patent/ES2895225T3/es active Active
- 2014-01-31 CA CA2898665A patent/CA2898665C/en active Active
- 2014-01-31 MX MX2015009950A patent/MX372934B/es active IP Right Grant
- 2014-01-31 JP JP2015555508A patent/JP6373280B2/ja active Active
- 2014-01-31 CN CN201710680673.XA patent/CN107485612B/zh active Active
- 2014-01-31 PL PL18158586T patent/PL3381917T3/pl unknown
- 2014-01-31 CN CN201480007024.8A patent/CN105246888B/zh active Active
- 2014-01-31 TR TR2018/07602T patent/TR201807602T4/tr unknown
- 2014-01-31 RU RU2015133450A patent/RU2656593C2/ru active
- 2014-01-31 PL PL14745722T patent/PL2951177T3/pl unknown
- 2014-01-31 DK DK14745722.0T patent/DK2951177T3/en active
- 2014-01-31 EP EP18158586.0A patent/EP3381917B1/en active Active
- 2014-01-31 PT PT18158586T patent/PT3381917T/pt unknown
-
2015
- 2015-01-30 NO NO15153188A patent/NO2910833T3/no unknown
-
2017
- 2017-02-02 US US15/423,428 patent/US9814725B2/en active Active
- 2017-09-26 US US15/716,410 patent/US9937185B2/en active Active
-
2018
- 2018-02-27 US US15/906,230 patent/US20190030040A1/en not_active Abandoned
-
2019
- 2019-04-04 US US16/375,773 patent/US20190231789A1/en not_active Abandoned
-
2020
- 2020-01-07 US US16/736,599 patent/US20200138826A1/en not_active Abandoned
- 2020-08-27 US US17/005,238 patent/US20200390779A1/en not_active Abandoned
-
2021
- 2021-04-08 US US17/225,753 patent/US20210228588A1/en not_active Abandoned
- 2021-11-10 US US17/523,767 patent/US20220062290A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX372934B (es) | Compuestos de imidazopiridina y sus usos. | |
| CO2018013978A2 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos. | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| MX377305B (es) | DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2. | |
| MX394082B (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim. | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2015012456A (es) | Compuestos heterociclicos y usos de los mismos. | |
| BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
| WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| JOP20180116A1 (ar) | H1- بيرازولو [4، 3-b] بيريدينات كمثبطات PDE1 | |
| EA201400182A1 (ru) | Производные пиридин-2(1н)-она в качестве ингибиторов jak | |
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
| EA201591541A1 (ru) | Ингибиторы бета-секретазы 1 (bace 1) | |
| MX367960B (es) | Procedimiento para la preparacion de (4s)-4-(4-ciano-2-metoxifenil o)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificacion para su uso como principio activo farmaceutico. | |
| MX384798B (es) | Piridinona dicarboxamida para uso como inhibidores de bromodominio. | |
| MX382347B (es) | Derivados de piridincarboxamida, su método de preparación y sus usos farmacéuticos. | |
| CL2013003056A1 (es) | Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas. | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| MX2015013414A (es) | N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa. | |
| EA201790179A1 (ru) | [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |